ArticleBritish journal of cancer2025
VASN drives gastric tumorigenesis via activation of the COL4A1/PI3K/AKT axis during Helicobacter pylori infection.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances inOncology letters · 2026Review
- VASN Enhances IGF2BP3 Stability via USP10 Deubiquitination to Promote Triple-negative Breast Cancer Paclitaxel Resistance.International journal of biological sciences · 2026Article
- Integrated single-cell and bulk transcriptomic analyses reveal a stem-like epithelial subpopulation in adenocarcinoma of the esophagogastric junction and identify VASN as a novel regulator of tumor stemness.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundVasorin (VASN) is linked to tumor progression in various cancers, its role and regulatory mechanisms in gastric cancer (GC) are still unknown.
methodsHuman gastric mucosal samples, VASN heterozygous-deficient (VASN
resultsElevated VASN expression was significantly associated with poor clinical outcomes in GC patients. We identified a strong correlation between increased VASN expression, driven by Helicobacter pylori (H. pylori) infection, and the progression of gastric carcinogenesis. Functional studies demonstrated that VASN overexpression enhanced the proliferation, migration, and invasion of gastric epithelial cells, whereas VASN knockdown suppressed these malignant phenotypes. Mechanistically, the collagen type IV alpha 1 chain (COL4A1) was identified as a critical downstream effector of VASN in GC. VASN exerted its oncogenic effects by regulating COL4A1 to activate the PI3K/AKT signaling pathway. Furthermore, H. pylori infection was demonstrated to induce hypoxia-inducible factor-1 alpha (HIF-1α) expression, which subsequently upregulated VASN.
conclusionsThe HIF-1α-VASN-COL4A1-PI3K/AKT signaling pathway is crucial for gastric tumor development and may represent a therapeutic target for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.